Cerevel Therapeutics Holdings, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. June 3, 2025; Deadline to file Lead Plaintiff Motion

Core Viewpoint - Cerevel Therapeutics Holdings, Inc. is facing a class action lawsuit from investors who purchased securities during the specified class period, alleging material omissions and misconduct related to a secondary stock offering and misleading statements regarding an acquisition by AbbVie [1][3]. Group 1: Class Action Details - The class action lawsuit represents investors who bought securities between October 11, 2023, and August 1, 2024, with a deadline for filing a lead plaintiff motion set for June 3, 2025 [1]. - The lawsuit claims that Cerevel's secondary stock offering on October 16, 2023, was manipulated by controlling shareholders Bain and Pfizer to allow Bain to increase its stake at a discounted price before AbbVie's acquisition announcement [3]. Group 2: Financial Implications - The complaint alleges that the offering price was significantly lower than the acquisition price of $45 per share announced by AbbVie just 51 days later, resulting in a windfall of over $120 million for Bain [3].